Summit Lens

AI can predict protein structures, search enormous chemical spaces, identify drug targets, and help design new molecules.

But building a molecule is only the beginning.

In this episode, we follow one fictional cancer drug, SL-101, through the modern R&D pipeline—from target discovery and medicinal chemistry to Phase II, biomarker selection, clinical trials, and one of the hardest decisions in pharma: whether to keep spending.

Along the way, we look at how companies such as Insilico Medicine, Recursion, Isomorphic Labs, Tempus, Schrödinger, and Unlearn are applying very different kinds of AI to very different problems.

The deeper question is whether AI can help pharma make better bets: choosing the right target, the right molecule, the right patient, and knowing when a program is no longer worth funding.

Timestamps

• 00:00 A Drug at a Crossroads
• 04:17 What Should We Drug? AI Target Discovery
• 13:16 What Molecule Should We Make?
• 20:50 When Biology Fights Back: Phase I vs. Phase II
• 30:00 Who Actually Responds? Biomarkers and Patient Selection
• 37:25 When Should We Stop Spending? The Value of Failing Early
• 42:04 Can AI Make Clinical Trials Better?
• 48:43 Who Owns the Value? Big Pharma vs. AI Biotech
• 53:02 A Sequence of Better Bets

AI can already read scans, flag high-risk patients, guide ultrasound exams, and even make some autonomous diagnostic decisions.

But that raises a more important question: does a better model actually lead to better care?

In this episode, we follow what happens after the algorithm gives an answer. We look at why GPT-4 did not automatically make physicians better diagnosticians, how AI cut mammography reading workload by 44%, why some clinical alerts become noise while others speed up stroke treatment, and what happens when AI moves expertise closer to the patient.

We also look at one of the rare randomized trials linking an AI alert to lower mortality—and why some of the fastest-moving healthcare AI may be doing something far less glamorous: writing the clinical note.

The real story of medical AI may not be whether machines can outperform doctors. It may be whether healthcare systems know what to do with what the machines find.

Timestamps

• 00:08 The rise of AI in medicine
• 05:33 When smart AI doesn’t automatically make a smarter team
• 09:14 When the workflow is designed around AI
• 13:31 When an alert becomes noise
• 19:25 When the signal reaches an outcome
• 22:33 Moving expertise closer to the patient
• 28:21 Why the “boring” AI may move faster
• 31:24 Who decides when AI is good enough for healthcare?

You may know your doctor.

But do you know who owns the business around your doctor?

Private equity usually does not show up in healthcare with a Wall Street label. It shows up more quietly, in the local practice that keeps its old name, the specialist group inside a hospital, or the clinic that suddenly feels more optimized than before.

The care may look familiar. The ownership may not be.

In this episode, we follow how private equity became one of the most important and least visible ownership forces in the US healthcare.

The story starts with the private equity model itself: raise capital, use leverage, buy a platform, add smaller practices, centralize operations, optimize revenue, and sell on a fund timeline.

Then we ask why healthcare fit that model so well.

The answer is uncomfortable: fragmented providers, opaque prices, third-party payment, complex billing, recurring demand, and physicians exhausted by the business side of medicine.

We follow that playbook from physician practices to emergency staffing, outpatient specialties, nursing homes, and hospital real estate.

This is not a simple story about private equity being good or bad.

Some practices need capital. Some physicians sell for rational reasons. Some platforms bring better technology and cleaner operations.

But when care becomes an investment asset, the logic around the exam room can change: what gets scheduled, what gets billed, which services grow, how doctors practice, and what patients experience without ever seeing the ownership change.

The takeaway is simple:

In the US healthcare, ownership is now part of the care model.

The question is no longer only, “Who is my doctor?”

It is also, “Who owns the system around my doctor and what is that owner optimized to do?”

Timestamps

• 00:07 When Healthcare Becomes an Investment Thesis
• 04:03 How the Private Equity Model Works
• 08:46 Why Healthcare Fit the Financial Engine
• 10:29 The Roll-Up Playbook
• 16:38 Envision, Surprise Billing, and the No Surprises Act
• 26:43 Specialty Roll-Ups and Outpatient Care
• 32:36 When Financial Engineering Hits High-Risk Care
• 39:31 What Changes for Doctors, Patients, and Prices
• 43:19 How Regulators Are Pushing Back
• 47:15 Who Owns the System Around Your Doctor?

Why can the same care cost more when the doctor, the room, and the service have not changed?

In this episode, we look at how hospitals became some of the most powerful price setters in American healthcare.

We start with a routine cardiology visit that suddenly costs almost three times more after the practice becomes part of a hospital system. From there, we unpack the larger structure behind that bill: hospital consolidation, must-have health systems, commercial prices, facility fees, physician practice acquisitions, and the policy fight over site-neutral payments.

This is not a simple story about hospitals being good or bad. Some health systems have enormous leverage. Some rural hospitals are barely staying open. And many policy solutions come with real tradeoffs.

But the central tension is clear: in healthcare, scale can create survival — and scale can create pricing power.

Timestamps

• 00:06 Why Hospitals Became the Price Setters
• 05:34 Hospitals as the Load-Bearing Wall of Healthcare Spending
• 12:10 Three Consolidation Playbooks
• 15:42 When the Bargaining Table Tips
• 19:07 Commercial Prices and the Cross-Subsidy Debate
• 25:21 Facility Fees and the Site-of-Care Economy
• 30:14 The Site-Neutrality Fight
• 33:06 Physician Practice Acquisition and Referral Control
• 34:27 The Anticompetitive Mechanisms Behind Doctor Buyouts
• 37:01 The Invisibility Problem in Healthcare Acquisitions
• 40:50 The Rural Hospital Tradeoff
• 45:15 Four Ways the System Pushes Back
• 52:37 Why Hospital Market Power Matters

What does it actually mean to have health insurance in America?

In this episode, we look at the Affordable Care Act not as a partisan debate, but as a systems story.

The ACA changed who could enter the insurance market. It made it harder for insurers to deny coverage because of pre-existing conditions, removed annual and lifetime limits, expanded Medicaid in many states, and created subsidized marketplaces for people outside employer coverage.

But it did not fully change what care costs once someone gets inside the system.

So the central question is not simply whether the ACA succeeded or failed. It is what kind of problem the law was built to solve, and what kind of problem it left behind.

We follow that question from a kitchen table during open enrollment to pre-ACA medical underwriting, marketplace plan design, narrow networks, underinsurance, Medicaid expansion, temporary subsidies, and the deeper cost structure underneath American healthcare.

Because having insurance is not always the same as being able to afford care.

Timestamps

• 00:05 Why Having Insurance Still Feels Expensive
• 05:47 Before the ACA: The Exclusion Problem
• 13:36 How the ACA Rebuilt Insurance
• 22:41 When Coverage Is Hard to Use
• 33:16 Why Premiums and Deductibles Keep Rising
• 38:42 The Medicaid Expansion Divide
• 44:15 Temporary Subsidies and the 2026 Shock
• 48:39 What the ACA Solved and What It Didn’t
• 54:40 The Core Tradeoff and What Comes Next

What happens when Medicare stops only paying for drugs and starts naming the price?

In this episode, we look at the Inflation Reduction Act and Medicare drug price negotiation, not as a policy explainer, but as a shift in power inside the U.S. drug market.

For nearly two decades, Medicare Part D relied on private plans, PBMs, formularies, and rebates to negotiate drug costs. The IRA changed that architecture. Washington is now setting prices for selected high-spend Medicare drugs, and every part of the system is adapting around that new signal.

We follow the story from the pharmacy counter to the manufacturer revenue model, the Part D plan bid, the PBM rebate negotiation, and the biotech investment decision.

The question is no longer only whether Medicare can negotiate a lower price. It is what happens when that price becomes part of the operating system for the US drug markets.

Timestamps

• 00:10 Drug Pricing and the IRA
• 05:15 Medicare’s Old Bargain
• 10:05 How Washington Names a Price
• 13:46 Which Drugs Got Picked and Why
• 27:54 The Hidden Half: Part D Redesign
• 37:33 Pharma’s Strategic Response
• 46:32 PBMs Adapt, Not Disappear
• 51:00 What Patients Actually Experience
• 56:55 The New Price Signal

GLP-1 proved the science could work. The harder test began once patients tried to get it.

In this episode, we follow GLP-1 from the pharmacy counter into the real world of American healthcare: insurance coverage, compounding pharmacies, PBM formulary decisions, employer benefit design, cash pay pathways, TrumpRx, and public policy.

The question is no longer only whether these drugs work. It is how the system decides who gets access when a treatment is effective, expensive, highly demanded, and potentially preventive.

And for many patients, the answer depends on which door is actually open.

Timestamps

• 00:06  When the Prescription Isn’t Enough
• 07:47  How Compounding Became the Workaround
• 10:58  Why Coverage Still Creates Friction
• 16:17  Public Coverage and International Contrasts
• 21:53  PBMs, Employers, and the Formulary Fight
• 28:56  Cash Pay, TrumpRx, and New Access Lanes
• 35:19  The Pipeline Keeps Moving
• 35:48  Who Pays for Prevention?

How did a gut hormone that disappeared in seconds become one of the biggest drug classes in the world?

In this episode, I walk through the story of GLP-1, from early scientific discovery and the Gila monster breakthrough to Novo Nordisk’s drug design strategy, Eli Lilly’s competitive push, and the shift that turned GLP-1 from a diabetes treatment into something much bigger.

This is a story about how a hard biological problem became a pharmaceutical platform, and how that platform began to change the way medicine thinks about obesity, metabolism, and chronic disease.

Timestamps

• 00:08 Intro: The 90-Second Hormone
• 02:23 The Gut’s Hidden Signal
• 05:01 The Discovery of GLP-1
• 10:32 The Gila Monster Breakthrough
• 16:04 Novo Solves the Delivery Problem
• 19:43 How GLP-1 Became a Platform
• 25:46 Beyond Diabetes
• 30:28 Lilly Raises the Benchmark
• 32:43 The Broader Implications of GLP-1
• 43:22 The future of GLP-1
• 49:14 When the Science Meets the System

What does it actually take to turn a scientific breakthrough into a drug patients can access?

In this episode, I look at the manufacturer side of the healthcare system, the part that absorbs scientific failure, funds long-shot bets, and then enters a second battle after the science succeeds. Because FDA approval is not the finish line. It is the point where a therapy enters the real commercial system: one shaped by patent clocks, launch pricing, payer resistance, formulary access, rebates, and budget pressure.

This is a story about the economics of failure, the logic of blockbuster drugs, and the central tension at the heart of modern pharma: scientifically essential, politically unpopular, financially powerful, and commercially constrained at the same time.

Between the lab bench and the patient sits a market that does not simply reward innovation. It prices it, filters it, delays it, and redistributes its value.

Timestamps

• 00:00 Intro: The Drug Exists. Access Still Breaks Down
• 05:44 FDA Approval Is Not the Finish Line
• 09:41 Inside the R&D Risk Machine
• 13:24 Why Most Drug Trials Fail
• 15:32 The Patent Clock Starts Early
• 24:39 Why U.S. Drug Prices Run Higher
• 29:19 The Gross-to-Net Bubble
• 40:16 The Pharma Paradox
• 44:05 The IRA Changes the Game
• 50:59 Invention Is Not Enough

If your doctor writes a prescription, who actually decides whether you get it, where you fill it, and what you pay?

In this episode, I unpack the hidden role of pharmacy benefit managers, or PBMs, the intermediaries that sit between drugmakers, insurers, employers, pharmacies, and patients. PBMs do not invent drugs or prescribe them, but they often control formularies, prior authorization, specialty pharmacy channels, and the financial terms that shape access.

I trace how PBMs evolved from claims processors into powerful gatekeepers, explain how rebates, spread pricing, specialty pharmacy, and step therapy work, and examine the central debate: are PBMs lowering costs, or making the system more opaque while controlling who gets what medicine?

From insulin and biosimilars to specialty drug markups and the latest reform pressure, this is a story about the financial architecture between the prescription pad and the patient.

Timestamps

• 00:00 — Cold open
• 03:23 — The pharmacy counter mystery
• 12:28 — Meet the PBM
• 16:35 — The evolution of PBMs
• 22:25 — How the machine works
• 38:01 — Why PBMs grew so powerful
• 49:33 — Critics vs. Defense
• 57:01 — What this means